{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:50:07Z","timestamp":1772722207570,"version":"3.50.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"pituitary research society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s42000-021-00333-y","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T14:02:45Z","timestamp":1642773765000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["High-risk pituitary adenomas and strategies for predicting response to treatment"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-8196","authenticated-orcid":false,"given":"George","family":"Kontogeorgos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Thodou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Y.","family":"Osamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo V.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"5","key":"333_CR1","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/jc.2004-2231","volume":"90","author":"GA Kaltsas","year":"2005","unstructured":"Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089\u20133099. https:\/\/doi.org\/10.1210\/jc.2004-2231","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"333_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10143-014-0525-y","volume":"37","author":"TM Hansen","year":"2014","unstructured":"Hansen TM, Batra S, Lim M, Burger PC, Salvatori R, Wand G, Quinones-Hinojosa A, Kleinberg L, Redmond KJ (2014) Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev 37(2):279\u2013286. https:\/\/doi.org\/10.1007\/s10143-014-0525-y","journal-title":"Neurosurg Rev"},{"issue":"10","key":"333_CR3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1517\/14656566.2011.568478","volume":"12","author":"A Colao","year":"2011","unstructured":"Colao A, Grasso LF, Pivonello R, Lombardi G (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12(10):1561\u20131570. https:\/\/doi.org\/10.1517\/14656566.2011.568478","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"333_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","volume":"10","author":"A Di Ieva","year":"2014","unstructured":"Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas-diagnosis and emerging treatments. Nat Rev Endocrinol 10(7):423\u2013435. https:\/\/doi.org\/10.1038\/nrendo.2014.64","journal-title":"Nat Rev Endocrinol"},{"key":"333_CR5","doi-asserted-by":"publisher","unstructured":"Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74(4):E447\u2013E455; discussion E455. https:\/\/doi.org\/10.1227\/NEU.0000000000000251","DOI":"10.1227\/NEU.0000000000000251"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"608422","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne) 11:608422. https:\/\/doi.org\/10.3389\/fendo.2020.608422","journal-title":"Front Endocrinol (Lausanne)"},{"key":"333_CR7","first-page":"13","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"RY Osamura","year":"2017","unstructured":"Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Tumours of the pituitary gland. Introduction. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J (eds) WHO Classification of Tumours of Endocrine Organs, vol 10, 4th edn. IARC, Lyon, p 13","edition":"4"},{"key":"333_CR8","first-page":"14","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"R Osamura","year":"2017","unstructured":"Osamura R, Grossman A, Korbonits M, Kovacs K, Lopes MBS, Matsuro A, Trouillas J (2017) Pituitary gland: pituitary adenoma. In: Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J (eds) WHO Classification of Tumours of Endocrine Organs, vol 10, 4th edn. IARC, Lyon, pp 14\u201318","edition":"4"},{"issue":"3","key":"333_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P (2018) ESE survey collaborators. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey. Eur J Endocrinol 178(3):265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933","journal-title":"Eur J Endocrinol"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol"},{"issue":"2","key":"333_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1530\/EJE-18-0749","volume":"180","author":"S Asioli","year":"2019","unstructured":"Asioli S, Righi A, Iommi M, Baldovini C, Ambrosi F, Guaraldi F, Zoli M, Mazzatenta D, Faustini-Fustini M, Rucci P, Giannini C, Foschini MP (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180(2):127\u2013134. https:\/\/doi.org\/10.1530\/EJE-18-0749","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"333_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cen.14197","volume":"93","author":"F Guaraldi","year":"2020","unstructured":"Guaraldi F, Zoli M, Righi A, Gibertoni D, Marino Picciola V, Faustini-Fustini M, Morandi L, Bacci A, Pasquini E, Mazzatenta D, Asioli S (2020) A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s. Clin Endocrinol (Oxf) 93(1):36\u201343. https:\/\/doi.org\/10.1111\/cen.14197","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"333_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","volume":"475","author":"C Villa","year":"2019","unstructured":"Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F (2019) A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 475(6):687\u2013692. https:\/\/doi.org\/10.1007\/s00428-019-02655-0","journal-title":"Virchows Arch"},{"issue":"3","key":"333_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11102-019-01015-0","volume":"23","author":"SL Asa","year":"2020","unstructured":"Asa SL, Asioli S, Bozkurt S, Casar-Borota O, Chinezu L, Comunoglu N, Cossu G, Cusimano M, Delgrange E, Earls P, Ezzat S, Gazioglu N, Grossman A, Guaraldi F, Hickman RA, Ikeda H, Jaffrain-Rea ML, Karavitaki N, Kraljevi\u0107 I, La Rosa S, Manojlovi\u0107-Ga\u010di\u0107 E, Maartens N, McCutcheon IE, Messerer M, Mete O, Nishioka H, Oz B, Pakbaz S, Pekmezci M, Perry A, Reiniger L, Roncaroli F, Saeger W, S\u00f6ylemezo\u011flu F, Tachibana O, Trouillas J, Turchini J, Uccella S, Villa C, Yamada S, Yarman S (2020) Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary 23(3):322\u2013325. https:\/\/doi.org\/10.1007\/s11102-019-01015-0","journal-title":"Pituitary"},{"key":"333_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","volume":"22","author":"KKY Ho","year":"2019","unstructured":"Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, Melmed S (2019) A tale of pituitary adenomas: to NET or not to NET. Pituitary Society position statement. Pituitary 22:569\u2013573. https:\/\/doi.org\/10.1007\/s11102-019-00988-2","journal-title":"Pituitary"},{"issue":"3","key":"333_CR16","doi-asserted-by":"publisher","first-page":"bvaa205","DOI":"10.1210\/jendso\/bvaa205","volume":"5","author":"K Ho","year":"2021","unstructured":"Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S (2021) Pituitary neoplasm nomenclature workshop: does adenoma stand the test of time? J Endocr Soc 5(3):bvaa205. https:\/\/doi.org\/10.1210\/jendso\/bvaa205","journal-title":"J Endocr Soc"},{"key":"333_CR17","doi-asserted-by":"publisher","unstructured":"Giustina A. Pituitary adenoma\u2026nomen omen? (2021) Endocrine, Jun 10, Online ahead of print. https:\/\/doi.org\/10.1007\/s12020-021-02785-z","DOI":"10.1007\/s12020-021-02785-z"},{"key":"333_CR18","unstructured":"Kovacs K, Horvath E (1986) Tumors of pituitary gland. Atlas of tumor pathology, 2nd series, fascicle 21. AFIP, Washington (DC)"},{"issue":"5","key":"333_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0344-0338(11)80135-4","volume":"187","author":"T Sano","year":"1991","unstructured":"Sano T, Ohsims T, Yamada S (1991) Expression of glycoprotein hormones and intracytoplsmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Path Res Pract 187(5):530\u2013533. https:\/\/doi.org\/10.1016\/S0344-0338(11)80135-4","journal-title":"Path Res Pract"},{"issue":"11","key":"333_CR20","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/jcm8111962","volume":"8","author":"A Akirov","year":"2019","unstructured":"Akirov A, Asa SL, Amer L, Shimon I, Ezzat S (2019) The clinicopathological spectrum of acromegaly. J Clin Med 8(11):1962. https:\/\/doi.org\/10.3390\/jcm8111962","journal-title":"J Clin Med"},{"issue":"2","key":"333_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","volume":"24","author":"AA Swanson","year":"2021","unstructured":"Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD, Erickson BJ, Giannini C (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192\u2013206. https:\/\/doi.org\/10.1007\/s11102-020-01096-2","journal-title":"Pituitary"},{"issue":"2","key":"333_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","volume":"19","author":"A Obari","year":"2008","unstructured":"Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82\u201391. https:\/\/doi.org\/10.1007\/s12022-008-9029-z","journal-title":"Endocr Pathol"},{"issue":"4","key":"333_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","volume":"16","author":"J Brzana","year":"2013","unstructured":"Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490\u2013498. https:\/\/doi.org\/10.1007\/s11102-012-0445-1","journal-title":"Pituitary"},{"key":"333_CR24","doi-asserted-by":"crossref","unstructured":"Asa SL (2011) Tumors of the pituitary gland. 2nd series. AFIP, Washington (DC)","DOI":"10.55418\/9781933477152"},{"issue":"4","key":"333_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-12-0864","volume":"168","author":"S Larkin","year":"2013","unstructured":"Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491\u2013419. https:\/\/doi.org\/10.1530\/EJE-12-0864","journal-title":"Eur J Endocrinol"},{"issue":"417","key":"333_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","volume":"5","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt- DeMasters BK, Wierman ME (2015) Differential somatostatin receptor (SSTR) 1\u20135 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 5(417):73\u201383. https:\/\/doi.org\/10.1016\/j.mce.2015.09.016","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"333_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cen.14465","volume":"95","author":"L Heng","year":"2021","unstructured":"Heng L, Liu X, Jia D, Guo W, Zhang S, Gao G, Gong L, Qu Y (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 95(1):134\u2013142. https:\/\/doi.org\/10.1111\/cen.14465","journal-title":"Clin Endocrinol (Oxf)"},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinol 101:87\u2013104. https:\/\/doi.org\/10.1159\/000371806","journal-title":"Neuroendocrinol"},{"issue":"6236","key":"333_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/340692a0","volume":"340","author":"CA Landis","year":"1989","unstructured":"Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340(6236):692\u2013696. https:\/\/doi.org\/10.1038\/340692a0","journal-title":"Nature"},{"issue":"3","key":"333_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1507\/endocrj.ej11-0177","volume":"59","author":"M Kato","year":"2012","unstructured":"Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T, Yamada S, Hirata Y (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221\u2013228. https:\/\/doi.org\/10.1507\/endocrj.ej11-0177","journal-title":"Endocr J"},{"issue":"3","key":"333_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.semdp.2013.06.002","volume":"30","author":"O Mete","year":"2013","unstructured":"Mete O, Asa SL (2013) Therapeutic implications of accurate classification of pituitary adenomas. Sem Diagn Pathol 30(3):158\u2013164. https:\/\/doi.org\/10.1053\/j.semdp.2013.06.002","journal-title":"Sem Diagn Pathol"},{"issue":"4","key":"333_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1530\/EJE-13-0134","volume":"169","author":"B Mayr","year":"2013","unstructured":"Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schofl C (2013) Molecular and functional properties of densely and sparsely-granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391\u2013400. https:\/\/doi.org\/10.1530\/EJE-13-0134","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"333_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","volume":"23","author":"I Potorac","year":"2016","unstructured":"Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Sch\u00f6fl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871\u2013881. https:\/\/doi.org\/10.1530\/ERC-16-0356","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"333_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1530\/eje.0.1330686","volume":"133","author":"S Ezzat","year":"1995","unstructured":"Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133(6):686\u2013690. https:\/\/doi.org\/10.1530\/eje.0.1330686","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"333_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11102-020-01077-5","volume":"23","author":"YW Park","year":"2020","unstructured":"Park YW, Kang Y, Ahn SS, Ku CR, Kim EH, Kim SH, Lee EJ, Kim SH, Lee SK (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23(6):691\u2013700. https:\/\/doi.org\/10.1007\/s11102-020-01077-5","journal-title":"Pituitary"},{"issue":"3","key":"333_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/07357907.2013.775293","volume":"31","author":"M Batisse","year":"2013","unstructured":"Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31(3):190\u2013196. https:\/\/doi.org\/10.3109\/07357907.2013.775293","journal-title":"Cancer Invest"},{"issue":"1","key":"333_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-014-0056-y","volume":"33","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li J, Tohti M, Hu Y, Wang S, Li W, Lu Z, Ma C (2014) The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res 33(1):56. https:\/\/doi.org\/10.1186\/s13046-014-0056-y","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"333_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12020-011-9485-y","volume":"40","author":"SS Zuhur","year":"2011","unstructured":"Zuhur SS, Tanik C, Karaman \u00d6, Velet S, \u00c7il E, \u00d6zt\u00fcrk FY, \u00d6zkayalar H, M\u00fcsl\u00fcman AM, Altunta\u015f Y (2011) MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 40(2):222\u2013227. https:\/\/doi.org\/10.1007\/s12020-011-9485-y","journal-title":"Endocrine"},{"issue":"6","key":"333_CR39","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170(6):R213\u2013R227. https:\/\/doi.org\/10.1530\/EJE-14-0013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"333_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000499702","volume":"11","author":"J P\u00e9rez Pinz\u00f3n","year":"2019","unstructured":"P\u00e9rez Pinz\u00f3n J, Gonz\u00e1lez-Devia D, Kattah Calder\u00f3n W, L\u00f3pez Panqueva RDP, Jim\u00e9nez Hakim E (2019) Unusual course of an aggressive pituitary prolactinoma: case report and review of the literature. Case Rep Neurol 11(1):148\u2013156. https:\/\/doi.org\/10.1159\/000499702","journal-title":"Case Rep Neurol"},{"issue":"3","key":"333_CR41","first-page":"104","volume":"68","author":"M Kars","year":"2010","unstructured":"Kars M, Dekkers OM, Pereira AM, Romijn JA (2010) Update in prolactinomas. Neth J Med 68(3):104\u2013112","journal-title":"Neth J Med"},{"issue":"1","key":"333_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000495184","volume":"109","author":"I Shimon","year":"2019","unstructured":"Shimon I (2019) Giant prolactinomas. Neuroendocrinology 109(1):51\u201356. https:\/\/doi.org\/10.1159\/000495184","journal-title":"Neuroendocrinology"},{"issue":"6","key":"333_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","volume":"172","author":"E Delgrange","year":"2015","unstructured":"Delgrange E, Vasiljevic A, Wierinckx A, Fran\u00e7ois P, Jouanneau E, Raverot G, Trouillas J (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791\u2013801. https:\/\/doi.org\/10.1530\/EJE-14-0990","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"333_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14310\/horm.2002.1729","volume":"16","author":"MH Almalki","year":"2017","unstructured":"Almalki MH, Aljoaib NN, Alotaibi MJ, Aldabas BS, Wahedi TS, Ahmad MM, Alshahrani F (2017) Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. Hormones (Athens) 16(2):139\u2013149. https:\/\/doi.org\/10.14310\/horm.2002.1729","journal-title":"Hormones (Athens)"},{"issue":"3","key":"333_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325\u2013331. https:\/\/doi.org\/10.1530\/eje.0.1480325","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"333_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17446651.2019.1596024","volume":"14","author":"N Sahakian","year":"2019","unstructured":"Sahakian N, Castinetti F, Dufour H, Graillon T, Romanet P, Barlier A, Brue T, Cuny T (2019) Clinical management of difficult to treat macroprolactinomas. Expert Rev Endocrinol Metab 14(3):179\u2013192. https:\/\/doi.org\/10.1080\/17446651.2019.1596024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"333_CR47","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1210\/jc.2014-3670","volume":"100","author":"S Salenave","year":"2015","unstructured":"Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenick\u00fd P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon PF, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P (2015) Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100(3):1177\u20131186. https:\/\/doi.org\/10.1210\/jc.2014-3670","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"333_CR48","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1210\/jcem.85.12.7064","volume":"85","author":"CA Stratakis","year":"2000","unstructured":"Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, Skarulis MC, Weil RJ, Lubensky IA, Zhuang Z, Oldfield EH, Marx SJ (2000) Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 85(12):4776\u20134780. https:\/\/doi.org\/10.1210\/jcem.85.12.7064","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"333_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1365-2265.2001.01031.x","volume":"54","author":"G Kontogeorgos","year":"2001","unstructured":"Kontogeorgos G, Kapranos N, Tzavara I, Thalassinos N, Rologis D (2001) Monosomy of chromosome 11 in pituitary adenoma in a patient with familial multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 54(1):117\u2013120. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01031.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"333_CR50","doi-asserted-by":"publisher","unstructured":"Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol (1):185\u2013189. Erratum in: Hum Pathol 38(3):526. https:\/\/doi.org\/10.1016\/j.humpath.2006.07.014","DOI":"10.1016\/j.humpath.2006.07.014"},{"issue":"4","key":"333_CR51","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2265.2006.02653.x","volume":"65","author":"LV Syro","year":"2006","unstructured":"Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552\u2013553. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02653.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"333_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","volume":"20","author":"C Halevy","year":"2017","unstructured":"Halevy C, Whitelaw BC (2017) How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary 20(2):261\u2013266. https:\/\/doi.org\/10.1007\/s11102-016-0745-y","journal-title":"Pituitary"},{"key":"333_CR53","doi-asserted-by":"publisher","unstructured":"Zampetti B, Simonetti G, Attanasio R, Silvani A, Cozzi R (2018) Effective long-term temozolomide rechallenge in a macroprolactinoma. Endocrinol Diabetes Metab Case Rep 18-0092. https:\/\/doi.org\/10.1530\/EDM-18-0092","DOI":"10.1530\/EDM-18-0092"},{"issue":"4","key":"333_CR54","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen \u00c5K, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698. https:\/\/doi.org\/10.1210\/jc.2014-4350","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"333_CR55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","volume":"76","author":"BC Whitelaw","year":"2012","unstructured":"Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJ (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76(6):877\u2013886. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04373.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"333_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low 06-methylguanine-DNA methyltransferase [p1] (mgmt) expression and response to temozolomide in aggressive pituitary tumors. Clin Endocrinol (Oxf) 71(2):226\u2013233. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03487.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"333_CR57","doi-asserted-by":"publisher","first-page":"E1761","DOI":"10.1227\/NEU.0b013e318217161a","volume":"68","author":"M Murakami","year":"2011","unstructured":"Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurg 68:E1761\u2013E1767. https:\/\/doi.org\/10.1227\/NEU.0b013e318217161a","journal-title":"Neurosurg"},{"key":"333_CR58","doi-asserted-by":"publisher","unstructured":"Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ER Jr, Young WF Jr (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47(3):723\u2013729; discussion 729\u2013730. https:\/\/doi.org\/10.1097\/00006123-200009000-00039","DOI":"10.1097\/00006123-200009000-00039"},{"issue":"2","key":"333_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14310\/horm.2002.1307","volume":"10","author":"O Moshkin","year":"2011","unstructured":"Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 10(2):162\u2013167. https:\/\/doi.org\/10.14310\/horm.2002.1307","journal-title":"Hormones (Athens)"},{"issue":"4","key":"333_CR60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ijrobp.2014.07.013","volume":"90","author":"Z Xu","year":"2014","unstructured":"Xu Z, Ellis S, Lee CC, Starke Lee Vance M, Lopes MB, Sheehan J (2014) Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study. Int J Radiat Oncol Biol Phys 90(4):903\u2013910. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.07.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"333_CR61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","volume":"26","author":"H Nishioka","year":"2015","unstructured":"Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26(4):349\u2013355. https:\/\/doi.org\/10.1007\/s12022-015-9398-z","journal-title":"Endocr Pathol"},{"issue":"3","key":"333_CR62","first-page":"227","volume":"6","author":"E Thodou","year":"2007","unstructured":"Thodou E, Argyrakos T, Kontogeorgos G (2007) Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 6(3):227\u2013232","journal-title":"Hormones (Athens)"},{"issue":"2","key":"333_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1385\/ep:16:2:107","volume":"16","author":"L Jin","year":"2005","unstructured":"Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV (2005) Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol 16(2):107\u2013114. https:\/\/doi.org\/10.1385\/ep:16:2:107","journal-title":"Endocr Pathol"},{"issue":"4","key":"333_CR64","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1507\/endocrj.k08e-186","volume":"56","author":"T Tateno","year":"2009","unstructured":"Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y (2009) Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56(4):579\u2013584. https:\/\/doi.org\/10.1507\/endocrj.k08e-186","journal-title":"Endocr J"},{"issue":"11","key":"333_CR65","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342\u20134350. https:\/\/doi.org\/10.1210\/jc.2009-1311","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"333_CR66","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1507\/endocrj.EJ18-0547","volume":"66","author":"S Tanaka","year":"2019","unstructured":"Tanaka S, Yamamoto M, Morita M, Takeno A, Kanazawa I, Yamaguchi T, Yamada S, Inoshita N, Oki Y, Kurosaki M, Sugimoto T (2019) Successful reduction of ACTH secretion in a case of intractable Cushing\u2019s disease with pituitary Crooke\u2019s cell adenoma by combined modality therapy including temozolomide. Endocr J 66(8):701\u2013708. https:\/\/doi.org\/10.1507\/endocrj.EJ18-0547","journal-title":"Endocr J"},{"issue":"3\u20134","key":"333_CR67","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF01407130","volume":"58","author":"IA Felix","year":"1981","unstructured":"Felix IA, Horvath E, Kovacs K (1981) Massive Crooke\u2019s hyalinization in corticotroph cell adenomas of the human pituitary: a histological, immunocytological and electron microscopic study of three cases. Acta Neurochir (Wien) 58(3\u20134):235\u2013243. https:\/\/doi.org\/10.1007\/BF01407130","journal-title":"Acta Neurochir (Wien)"},{"issue":"10","key":"333_CR68","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1097\/00000478-200310000-00005","volume":"27","author":"DH George","year":"2003","unstructured":"George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB (2003) Crooke\u2019s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27(10):1330\u20131336. https:\/\/doi.org\/10.1097\/00000478-200310000-00005","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"333_CR69","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1210\/jc.2011-2031","volume":"96","author":"AP Heaney","year":"2011","unstructured":"Heaney AP (2011) Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649\u20133660. https:\/\/doi.org\/10.1210\/jc.2011-2031","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"333_CR70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11060-014-1413-6","volume":"117","author":"A Heaney","year":"2014","unstructured":"Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117(3):459\u2013468. https:\/\/doi.org\/10.1007\/s11060-014-1413-6","journal-title":"J Neurooncol"},{"key":"333_CR71","doi-asserted-by":"publisher","unstructured":"Giri D, Roncaroli F, Sinha A, Didi M, Senniappan S (2017) Silent Crooke\u2019s cell corticotroph adenoma of the pituitary gland presenting as delayed puberty. Endocrinol Diabetes Metab Case Rep 16-0153. https:\/\/doi.org\/10.1530\/EDM-16-0153","DOI":"10.1530\/EDM-16-0153"},{"issue":"1","key":"333_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ccr3.39","volume":"2","author":"A Asimakopoulou","year":"2014","unstructured":"Asimakopoulou A, Tzanela M, Kontogeorgos KA, G, Tsagarakis S, (2014) Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide. Clin Case Rep 2(1):1\u20133. https:\/\/doi.org\/10.1002\/ccr3.39","journal-title":"Clin Case Rep"},{"issue":"2","key":"333_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11154-019-09534-8","volume":"21","author":"C Tatsi","year":"2020","unstructured":"Tatsi C, Stratakis CA (2020) Aggressive pituitary tumors in the young and elderly. Rev Endocr Metab Disord 21(2):213\u2013223. https:\/\/doi.org\/10.1007\/s11154-019-09534-8","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 1","key":"333_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.6061\/clinics\/2012(sup01)20","volume":"67","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo, Brazil) 67(Suppl 1):119\u2013123. https:\/\/doi.org\/10.6061\/clinics\/2012(sup01)20","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"3","key":"333_CR75","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2012-2924","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"333_CR76","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/01913120500323514","volume":"29","author":"E Horvath","year":"2005","unstructured":"Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29(6):511\u2013524. https:\/\/doi.org\/10.1080\/01913120500323514","journal-title":"Ultrastruct Pathol"},{"issue":"2","key":"333_CR77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/modpathol.2015.151","volume":"29","author":"O Mete","year":"2016","unstructured":"Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL (2016) Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 29(2):131\u2013142. https:\/\/doi.org\/10.1038\/modpathol.2015.151","journal-title":"Mod Pathol"},{"issue":"1","key":"333_CR78","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2265.2008.03514.x","volume":"71","author":"D Erickson","year":"2009","unstructured":"Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71(1):92\u201399. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03514.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3\u20134","key":"333_CR79","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/a:1009954409469","volume":"1","author":"RY Osamura","year":"1999","unstructured":"Osamura RY, Tahara S, Komatsubara K, Itoh Y, Kajiwara H, Kurotani R, Sanno N, Teramoto A (1999) Pit-1 positive alpha-subunit positive nonfunctioning human pituitary adenomas: a dedifferentiated GH cell lineage? Pituitary 1(3\u20134):269\u2013271. https:\/\/doi.org\/10.1023\/a:1009954409469","journal-title":"Pituitary"},{"issue":"4","key":"333_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1267\/ahc.09004","volume":"42","author":"RY Osamura","year":"2009","unstructured":"Osamura RY, Egashira N, Kajiya H, Takei M, Tobita M, Miyakoshi T, Inomoto C, Takekoshi S, Teramoto A (2009) Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution. Acta Histochem Cytochem 42(4):95\u2013104. https:\/\/doi.org\/10.1267\/ahc.09004","journal-title":"Acta Histochem Cytochem"},{"issue":"4","key":"333_CR81","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1750-3639.2012.00599.x","volume":"22","author":"O Mete","year":"2012","unstructured":"Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain Pathol 22(4):443\u2013453. https:\/\/doi.org\/10.1111\/j.1750-3639.2012.00599.x","journal-title":"Brain Pathol"},{"key":"333_CR82","doi-asserted-by":"publisher","first-page":"105865","DOI":"10.1016\/j.clineuro.2020.105865","volume":"195","author":"E Thodou","year":"2020","unstructured":"Thodou E, Kontogeorgos G (2020) Somatostatin receptor profile in pituitary thyrotroph adenomas. Clin Neurol Neurosurg 195:105865. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105865","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"333_CR83","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12022-009-9094-y","volume":"20","author":"EL Wang","year":"2009","unstructured":"Wang EL, Qian ZR, Yamada S, Rahman MM, Inosita N, Kageji T, Endo H, Kudo E, Sano T (2009) Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20(4):209\u2013220. https:\/\/doi.org\/10.1007\/s12022-009-9094-y","journal-title":"Endocr Pathol"},{"issue":"4","key":"333_CR84","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1210\/jcem.85.4.6548","volume":"85","author":"JM Kuhn","year":"2000","unstructured":"Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85(4):1487\u20131491. https:\/\/doi.org\/10.1210\/jcem.85.4.6548","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"333_CR85","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1089\/thy.2015.0041","volume":"25","author":"F Rimareix","year":"2015","unstructured":"Rimareix F, Grunenwald S, Vezzosi D, Rivi\u00e8re LD, Bennet A, Caron P (2015) Primary medical treatment of thyrotropin-secreting pituitary adenomas by first-generation somatostatin analogs: a case study of seven patients. Thyroid 25(8):877\u2013882. https:\/\/doi.org\/10.1089\/thy.2015.0041","journal-title":"Thyroid"},{"issue":"3","key":"333_CR86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12022-010-9120-0","volume":"21","author":"ME Fealey","year":"2010","unstructured":"Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV (2010) MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol 21(3):161\u2013165. https:\/\/doi.org\/10.1007\/s12022-010-9120-0","journal-title":"Endocr Pathol"},{"issue":"3","key":"333_CR87","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11060-011-0532-6","volume":"104","author":"F Salehi","year":"2011","unstructured":"Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV (2011) MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 104(3):647\u2013657. https:\/\/doi.org\/10.1007\/s11060-011-0532-6","journal-title":"J Neurooncol"},{"issue":"3","key":"333_CR88","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-011-9293-0","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157\u2013198. https:\/\/doi.org\/10.1007\/s10555-011-9293-0","journal-title":"Front Neuroendocrinol"},{"issue":"Suppl 1","key":"333_CR89","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47\u201355. https:\/\/doi.org\/10.1159\/000080741","journal-title":"Neuroendocrinology"},{"issue":"4","key":"333_CR90","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4):389\u2013427. https:\/\/doi.org\/10.1210\/er.2002-0007","journal-title":"Endocr Rev"},{"issue":"3","key":"333_CR91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1267\/ahc.12006","volume":"45","author":"G Mizutani","year":"2012","unstructured":"Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, Ohni S, Nemoto N (2012) Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem 45(3):167\u2013176. https:\/\/doi.org\/10.1267\/ahc.12006","journal-title":"Acta Histochem Cytochem"},{"issue":"8","key":"333_CR92","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s005950200128","volume":"32","author":"Y Oda","year":"2002","unstructured":"Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H (2002) Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 32(8):690\u2013694. https:\/\/doi.org\/10.1007\/s005950200128","journal-title":"Surg Today"},{"issue":"2","key":"333_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PAS.0b013e31823d07f3","volume":"36","author":"M K\u00f6rner","year":"2012","unstructured":"K\u00f6rner M, Waser B, Schonbrunn A, Perren A, Reubi JC (2012) Somatostatin receptor subtype 2a immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36(2):242\u2013252. https:\/\/doi.org\/10.1097\/PAS.0b013e31823d07f3","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"333_CR94","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H (2019) Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci 20(12):3049. https:\/\/doi.org\/10.3390\/ijms20123049","journal-title":"Int J Mol Sci"},{"issue":"11","key":"333_CR95","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172\u20131182. https:\/\/doi.org\/10.1038\/modpathol.3800954","journal-title":"Mod Pathol"},{"issue":"3","key":"333_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/cen.12775","volume":"83","author":"E Diakatou","year":"2015","unstructured":"Diakatou E, Alexandraki KI, Tsolakis AV, Kontogeorgos G, Chatzellis E, Leonti A, Kaltsas GA (2015) Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin Endocrinol (Oxf) 83(3):420\u2013428. https:\/\/doi.org\/10.1111\/cen.12775","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"333_CR97","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280-290. https:\/\/doi.org\/10.1210\/jc.2010-0441","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"333_CR98","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Fran\u00e7ois P, Jouanneau E, Passagia JG, Bernier M, Corn\u00e9lius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592\u20134599. https:\/\/doi.org\/10.1210\/jc.2010-0644","journal-title":"J Clin Endocrinol Metab"},{"key":"333_CR99","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fendo.2018.00318","volume":"9","author":"LV Syro","year":"2018","unstructured":"Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K (2018) Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions. Front Endocrinol (Lausanne) 9:318. https:\/\/doi.org\/10.3389\/fendo.2018.00318","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"333_CR100","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11102-017-0829-3","volume":"20","author":"ASG Micko","year":"2017","unstructured":"Micko ASG, W\u00f6hrer A, H\u00f6ftberger R, Vila G, Marosi C, Knosp E, Wolfsberger S (2017) MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary 20(6):643\u2013653. https:\/\/doi.org\/10.1007\/s11102-017-0829-3","journal-title":"Pituitary"},{"issue":"6","key":"333_CR101","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11102-019-00993-5","volume":"22","author":"G Kontogeorgos","year":"2019","unstructured":"Kontogeorgos G, Thodou E, Koutourousiou M, Kaltsas G, Seretis A (2019) MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications. Pituitary 22(6):614\u2013619. https:\/\/doi.org\/10.1007\/s11102-019-00993-5","journal-title":"Pituitary"},{"issue":"4","key":"333_CR102","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s42000-019-00145-1","volume":"18","author":"G Kontogeorgos","year":"2019","unstructured":"Kontogeorgos G, Thodou E (2019) Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities. Hormones (Athens) 18(4):333\u2013337. https:\/\/doi.org\/10.1007\/s42000-019-00145-1","journal-title":"Hormones (Athens)"},{"issue":"3","key":"333_CR103","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/10520299709082229","volume":"72","author":"N Kapranos","year":"1997","unstructured":"Kapranos N, Kontogeorgos G, Frangia K, Kokka E (1997) Effect of fixation on interphase cytogenetic analysis by direct fluorescence in situ hybridization on cell imprints. Biotech Histochem 72(3):148\u2013151. https:\/\/doi.org\/10.3109\/10520299709082229","journal-title":"Biotech Histochem"},{"issue":"3","key":"333_CR104","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s11102-018-0862-x","volume":"21","author":"ASG Micko","year":"2018","unstructured":"Micko ASG, H\u00f6ftberger R, W\u00f6hrer A, Millesi M, Knosp E, Wolfsberger S (2018) MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals. Pituitary 21(3):266\u2013273. https:\/\/doi.org\/10.1007\/s11102-018-0862-x","journal-title":"Pituitary"},{"issue":"10","key":"333_CR105","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","volume":"41","author":"AI McCormack","year":"2011","unstructured":"McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133\u20131148. https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02520.x","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"333_CR106","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/ERC-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska D, Grossman AB (2018) Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer 25(11):R559\u2013R575. https:\/\/doi.org\/10.1530\/ERC-18-0228","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"333_CR107","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","volume":"15","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15(3):445\u2013449. https:\/\/doi.org\/10.1007\/s11102-011-0346-8","journal-title":"Pituitary"},{"key":"333_CR108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E (2017) Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 41:75\u201377. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052","journal-title":"J Clin Neurosci"},{"issue":"2","key":"333_CR109","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","volume":"46","author":"O Cooper","year":"2014","unstructured":"Cooper O, Mamelak A, Bannykh S, Carmichael J, Bonert V, Lim S, Cook-Wiens G, Ben-Shlomo A (2014) Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine 46(2):318\u2013327. https:\/\/doi.org\/10.1007\/s12020-013-0093-x","journal-title":"Endocrine"},{"issue":"12","key":"333_CR110","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121(12):4712\u20134721. https:\/\/doi.org\/10.1172\/JCI60417","journal-title":"J Clin Invest"},{"issue":"4","key":"333_CR111","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MED.0000000000000344","volume":"24","author":"A Ben-Shlomo","year":"2017","unstructured":"Ben-Shlomo A, Cooper O (2017) Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside. Curr Opin Endocrinol Diabetes Obes 24(4):301\u2013305. https:\/\/doi.org\/10.1097\/MED.0000000000000344","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"333_CR112","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M, Melmed S (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925. https:\/\/doi.org\/10.1210\/clinem\/dgaa805","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"333_CR113","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","volume":"70","author":"V Cerovac","year":"2010","unstructured":"Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Can Res 70(2):666\u2013674. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2951","journal-title":"Can Res"},{"issue":"1","key":"333_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12022-012-9230-y","volume":"24","author":"EA Sajjad","year":"2013","unstructured":"Sajjad EA, Zieli\u0144ski G, Maksymowicz M, Hutnik \u0141, Bednarczuk T, W\u0142odarski P (2013) mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. Endocr Pathol 24(1):11\u201319. https:\/\/doi.org\/10.1007\/s12022-012-9230-y","journal-title":"Endocr Pathol"},{"issue":"4","key":"333_CR115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/cns-2016-0011","volume":"5","author":"LE Donovan","year":"2016","unstructured":"Donovan LE, Arnal AV, Wang SH, Odia Y (2016) Widely metastatic atypical pituitary adenoma with mTOR pathway STK11 (F298L) mutation treated with everolimus therapy. CNS Oncol 5(4):203\u2013209. https:\/\/doi.org\/10.2217\/cns-2016-0011","journal-title":"CNS Oncol"},{"issue":"6","key":"333_CR116","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D, Way JS, Zhang X, Sergey M, Bergsneider M, Wang MB, Yong WH, Heaney AP (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929\u20131936. https:\/\/doi.org\/10.1210\/jc.2018-02461","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"333_CR117","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","volume":"139","author":"PF Wang","year":"2018","unstructured":"Wang PF, Wang TJ, Yang YK, Yao K, Li Z, Li YM, Yan CX (2018) The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol 139(1):89\u201395. https:\/\/doi.org\/10.1007\/s11060-018-2844-2","journal-title":"J Neurooncol"},{"issue":"47","key":"333_CR118","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7(47):76565\u201376576","journal-title":"Oncotarget"},{"issue":"4","key":"333_CR119","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000100405","volume":"13","author":"SM Hazrati","year":"2006","unstructured":"Hazrati SM, Aghazadeh J, Mohtarami F, Abouzari M, Rashidi A (2006) Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report. NeuroImmunoModulation 13(4):205\u2013208. https:\/\/doi.org\/10.1159\/000100405","journal-title":"NeuroImmunoModulation"},{"issue":"10","key":"333_CR120","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, DeAngelis LM, Taylor BS, Young RJ, Geer EB (2018) Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930. https:\/\/doi.org\/10.1210\/jc.2018-01347","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"333_CR121","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/EC-19-0065","volume":"8","author":"G Giuffrida","year":"2019","unstructured":"Giuffrida G, Ferra\u00f9 F, Laudicella R, Cotta OR, Messina E, Granata F, Angileri FF, Vento A, Alibrandi A, Baldari S, Cannav\u00f2 S (2019) Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocr Connect 8(5):528\u2013535. https:\/\/doi.org\/10.1530\/EC-19-0065","journal-title":"Endocr Connect"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00333-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-021-00333-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00333-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T01:41:34Z","timestamp":1674524494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-021-00333-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s42000-021-00333-y","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain studies with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}